Drug Search Results
More Filters [+]

Mirtazapine

Alternative Names: mirtazapine, remeron, remeron soltab, mirtazepine, remeronsoltab, zispin
Latest Update: 2024-02-09
Latest Update Note: Clinical Trial Update

Product Description

Mirtazapine is an antidepressant medication that works in the brain. It is approved for the treatment of major depressive disorder (MDD). (Sourced from: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Mirtazapine-(Remeron))

Mechanisms of Action: 5-HT2A Antagonist,5-HT3A Antagonist,ADRA2A Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Depressive Disorder | Depressive Disorder, Major

Known Adverse Events: Dizziness | Weight Gain

Company: Meiji Seika Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Mirtazapine

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Depressive Disorder

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20223036

P1

Not yet recruiting

Depressive Disorder

None

Recent News Events